PTC Therapeutics PTCT Business Segments — Intangible Amortization
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's business segments — intangible amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's business segments — intangible amortization?
- PTC Therapeutics (PTCT) reported business segments — intangible amortization of $11.58M in Q1 2026.
- How has PTC Therapeutics's business segments — intangible amortization changed year-over-year?
- PTC Therapeutics's business segments — intangible amortization increased by 204.9% year-over-year, from $3.8M to $11.58M.
- What is the long-term trend for PTC Therapeutics's business segments — intangible amortization?
- Over 2 years (2023 to 2025), PTC Therapeutics's business segments — intangible amortization has grown at a -66.7% compound annual growth rate (CAGR), from $222.64M to $24.74M.
- What does business segments — intangible amortization mean?
- This metric represents the periodic expense recognized for the consumption of intangible assets, such as patents, licenses, or acquired intellectual property, within the Life Science segment. It reflects the gradual write-down of the value of non-physical assets that contribute to the segment's competitive advantage. Investors use this to evaluate the impact of past acquisitions and R&D investments on current earnings.